Evidence map›Paper›PMID 38746965›Full record

ArticleLa Tunisie medicale2024

Tubular expression of Toll-like receptor 9 in lupus and primary membranous nephropathy.

Nesrine Elloumi, Raouia Fakhfakh, Hatem Masmoudi, Khawla Kammoun

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in La Tunisie medicale, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nesrine ElloumiResearch laboratory LR18/SP12 auto-immunity, cancer, and immunogenetics, immunology department, Habib Bourguiba University Hospital, University of Sfax, Tunisia.
Raouia FakhfakhResearch laboratory LR18/SP12 auto-immunity, cancer, and immunogenetics, immunology department, Habib Bourguiba University Hospital, University of Sfax, Tunisia.
Hatem MasmoudiResearch laboratory LR18/SP12 auto-immunity, cancer, and immunogenetics, immunology department, Habib Bourguiba University Hospital, University of Sfax, Tunisia.
Khawla KammounResearch laboratory of renal pathology LR19ES11, Nephrology department, Hedi Chaker Hospital, University of Sfax, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionToll-like- receptors (TLR) control important aspects of innate and adaptive immune responses. Renal cells are among the non-immune cells that express (TLR). Therefore, their activation might be implicated in renal tubulo-interstitial injury.

aimThe study aimed to compare TLR9 expression in patients with primary membranous nephropathy (MN) to patients with lupus membranous nephropathy.

methodsKidney sections from 10 Lupus nephritis (LN) patients and ten patients with primary MN were analyzed by immunohistochemistry using anti-human TLR9 antibody.

resultsResults showed that TLR9 expression was weak and exclusively tubular in primary MN patients' biopsies. There was a significant difference between LN patients' biopsies and primary MN patients' biopsies. TLR9 expression was more diffused in LN patients' specimen than in those with primary MN.

conclusionThis study focuses on molecular level pathogenesis of MN. The data suggest that the receptors TLR9 may play role in tubulointerstitial injury in the pathogenesis of LN but not primary membranous nephropathy.

Indexed as

Glomerulonephritis, MembranousLupus NephritisToll-Like Receptor 9AdultBiopsyFemaleHumansImmunohistochemistryKidney TubulesMaleMiddle AgedYoung AdultTLR9 protein, humanToll-Like Receptor 9Kidney biopsiesLupus nephritisMembranous nephropathyTLR9Tubular expressionTubulointerstitial injury

Identifiers

PMID38746965
PMCPMC11358786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.